Effects on insulin sensitivity and body composition of combination therapy with GH and IGF1 in GH deficient adults with type 2 diabetes

European Journal of Endocrinology

Volumn 167, Issue 5, 2012, Pages 697-703

  Barner, Caroline ^a   Petersson, Maria ^b,c   Engström, Britt Edén ^d   Höybye, Charlotte ^b,c  

^a ST GÖRAN S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ABDOMINAL FAT; ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BODY COMPOSITION; BODY HEIGHT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PAROTID GLAND DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; WAIST CIRCUMFERENCE;

ADULT; AGED; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE CLAMP TECHNIQUE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84867492236     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0484     Document Type: Article

References (20)

1. Jørgensen JO, Krag M, Billestrup N & Christiansen JS. Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinology and Metabolism Clinics of North America 2007 36 75-87. (doi:10.1016/j.ecl.2006. 11.005)
2. Rosén T, Edén S, Larson G, Wilhelmsen L & Bengtsson BÅ. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinologica 1993 129 195-200. (Pubitemid 23295679)
3. Bulow B, Hagmar L, Mikoczy Z, Nordström CH & Erfurth EM. Increased cardiovascular mortality in patients with hypopituitarism. Clinical Endocrinology 1997 46 75-81. (doi:10.1046/j.1365-2265.1997.d01-1749.x)
4. Verhelst J & Abs R. Long-term growth hormone replacement therapy in hypopituitary adults. Drugs 2002 62 2399-2412. (doi:10.2165/00003495-200262160- 00006)
5. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. European Journal of Endocrinology 2003 148 S9-S14. (doi:10.1530/eje.0. 148S009)
6. Collett-Solberg PF, Misra M & on behalf of the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society . The role of recombinant human insulin-like growth factor-I in treating children with short stature. Journal of Clinical Endocrinology and Metabolism 2008 93 10-18. (doi:10.1210/jc.2007-1534)
7. Friedlander AL, Butterfield GE, Moynihan S, Grillo J, Pollack M, Holloway L, Friedman L, Yesavage J, Matthias D, Lee S, Marcus R & Hoffman AR. One year of insulin-like growth factor-I treatment does not affect bone density, body composition, or psychological measures in post-menopausal women. Journal of Clinical Endocrinology and Metabolism 2001 86 1496-1503. (doi:10.1210/jc.86.4. 1496)
8. McDonald A, Williams RM, Regan FM, Semple RK & Dunger DB. IGF-I treatment of insulin resistance. European Journal of Endocrinology 2007 157 S51-S56. (doi:10.1530/EJE-07-0271)
9. Kupfer SR, Underwood LE, Baxter RC & Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulinlike growth factor-I by use of both agents simultaneously. Journal of Clinical Investigation 1993 91 391-396. (doi:10.1172/JCI116212)
10. Hatton J, Kryscio R, Ryan M, Ott L & Young B. Systemic metabolic effects of combined insulin-like growth factor I and growth hormone therapy in patients who have sustained acute traumatic brain injury. Journal of Neurosurgery 2006 105 843-852. (doi:10.3171/jns.2006.105.6.843)
11. Thompson JL, Butterfield GE, Gylfadottir UK, Yesavage J, Marcus R, Hintz RL, Pearman A & Hoffman AR. Effects of human growth hormone, insulin-like growth factor-I and dietand exercise on body composition of obese postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1998 83 1477-1484. (doi:10.1210/jc.83.5.1477)
12. Janssen JA. Advantages and disadvantages of GH/IGF-I combination treatment. Reviews in Endocrine & Metabolic Disorders 2009 10 157-162. (doi:10.1007/s11154-008-9081-5)
13. Bang P, Eriksson U, Sara V, Wivall IL & Hall K. Comparison of acid ethanol extraction and gel filtration before IGF-I and IGF-II radioimmunoassay: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinologica 1991 124 620-629.
14. Povoa G, Roovete A & Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinologica 1984 107 563-570. (Pubitemid 15216173)
15. Hilding A, Hall K, Wivall-Helleryd IL, Saaf M, Melin AL & Thoren M. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. Journal of Clinical Endocrinology and Metabolism 1999 84 2013-2019. (doi:10. 1210/jc.84.6.2013)
16. DeFronzo RA, Tobin JD & Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology 1979 237 E214-E223. (Pubitemid 9249478)
17. Hussain M, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J & Froesch ER. Comparison of the effects of growth hormone and insulin-like growth factor 1 on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. Journal of Clinical Investigation 1994 94 1126-1133. (doi:10.1172/JCI117427)
18. Tam CS, Xie W, Johnson WD, Cefalu WT, Redman ML & Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care 2012 35 1605-1610. (doi:10.2337/dc11-2339)
19. Kotronen A, Lewitt M, Hall K, Brismar K & Yki-Jarvinen H. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. Journal of Clinical Endocrinology and Metabolism 2008 93 4867-4872. (doi:10. 1210/jc.2008-1245)
20. Salmenniemi U, Zacharova J, Routsalainen E, Vauhkonen I, Pihlajamäki J, Kainulainen S, Punnonen K & Laakso M. Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure and cytokines in offspring of type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 2005 90 4216-4223. (doi:10. 1210/jc.2004-2289)